HK1136823A1 - Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds - Google Patents

Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds

Info

Publication number
HK1136823A1
HK1136823A1 HK10100585.9A HK10100585A HK1136823A1 HK 1136823 A1 HK1136823 A1 HK 1136823A1 HK 10100585 A HK10100585 A HK 10100585A HK 1136823 A1 HK1136823 A1 HK 1136823A1
Authority
HK
Hong Kong
Prior art keywords
naphthalene
carboxylic acid
piperidine
compounds
substituted tetrahydro
Prior art date
Application number
HK10100585.9A
Other languages
English (en)
Inventor
Lieven Meerpoel
Joannes Theodorus Maria Linders
Libuse Jaroskova
Marcel Viellevoye
Leo Jacobus Jozef Backx
Didier Jean-Claude Berthelot
Guuske Frederike Busscher
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1136823A1 publication Critical patent/HK1136823A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK10100585.9A 2006-10-24 2010-01-20 Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds HK1136823A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06122817 2006-10-24
PCT/EP2007/061286 WO2008049806A1 (en) 2006-10-24 2007-10-22 Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds

Publications (1)

Publication Number Publication Date
HK1136823A1 true HK1136823A1 (en) 2010-07-09

Family

ID=37885794

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10100585.9A HK1136823A1 (en) 2006-10-24 2010-01-20 Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds

Country Status (28)

Country Link
US (1) US8114880B2 (ja)
EP (1) EP2076494B1 (ja)
JP (1) JP5506085B2 (ja)
KR (1) KR101415536B1 (ja)
CN (1) CN101528695B (ja)
AR (1) AR063517A1 (ja)
AT (1) ATE475648T1 (ja)
AU (1) AU2007310925B2 (ja)
BR (1) BRPI0717357A2 (ja)
CA (1) CA2664141C (ja)
CL (1) CL2007003042A1 (ja)
CY (1) CY1111010T1 (ja)
DE (1) DE602007008124D1 (ja)
DK (1) DK2076494T3 (ja)
EA (1) EA016311B1 (ja)
HK (1) HK1136823A1 (ja)
IL (1) IL198332A (ja)
JO (1) JO2653B1 (ja)
MX (1) MX2009004386A (ja)
NO (1) NO20092005L (ja)
NZ (1) NZ575615A (ja)
PL (1) PL2076494T3 (ja)
PT (1) PT2076494E (ja)
SI (1) SI2076494T1 (ja)
TW (1) TWI396688B (ja)
UA (1) UA99109C2 (ja)
WO (1) WO2008049806A1 (ja)
ZA (1) ZA200902822B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
ES2346014T3 (es) * 2006-10-24 2010-10-07 Janssen Pharmaceutica Nv Derivados del acido tetrahidro-naftaleno-1-carboxilico inhibidores de mtp.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
NO2629776T3 (ja) 2010-10-18 2018-01-13
PE20160122A1 (es) 2013-03-13 2016-02-12 Forma Therapeutics Inc Compuestos nobles y composiciones para la inhibicion de fasn
EP3484528B1 (en) 2016-07-18 2020-11-25 Janssen Pharmaceutica NV Tau pet imaging ligands
CN111902393B (zh) * 2018-05-15 2023-11-10 旭化成株式会社 氨基酸氨基烷基酯或其无机酸盐的制造方法
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
WO2024006701A1 (en) * 2022-06-28 2024-01-04 Stepan Company Method for making dialkyl amino acid ester sulfonates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
EP0832069B1 (en) 1995-06-07 2003-03-05 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
SK65499A3 (en) 1996-11-27 2001-05-10 Pfizer Apo b-secretion/mtp inhibitory amides
GB9826412D0 (en) 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
DE19963235A1 (de) 1999-12-27 2001-07-05 Boehringer Ingelheim Pharma Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
FR2816940A1 (fr) * 2000-11-23 2002-05-24 Lipha Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation
ES2346014T3 (es) 2006-10-24 2010-10-07 Janssen Pharmaceutica Nv Derivados del acido tetrahidro-naftaleno-1-carboxilico inhibidores de mtp.

Also Published As

Publication number Publication date
AR063517A1 (es) 2009-01-28
EA200970398A1 (ru) 2009-08-28
CN101528695A (zh) 2009-09-09
AU2007310925A1 (en) 2008-05-02
NO20092005L (no) 2009-06-04
CA2664141C (en) 2015-04-28
CN101528695B (zh) 2013-07-17
EP2076494B1 (en) 2010-07-28
EP2076494A1 (en) 2009-07-08
EA016311B1 (ru) 2012-04-30
CY1111010T1 (el) 2015-06-11
ATE475648T1 (de) 2010-08-15
MX2009004386A (es) 2009-05-08
US8114880B2 (en) 2012-02-14
KR101415536B1 (ko) 2014-07-16
IL198332A (en) 2012-08-30
TW200833680A (en) 2008-08-16
CA2664141A1 (en) 2008-05-02
TWI396688B (zh) 2013-05-21
CL2007003042A1 (es) 2008-05-02
JP5506085B2 (ja) 2014-05-28
PL2076494T3 (pl) 2011-01-31
KR20090075832A (ko) 2009-07-09
BRPI0717357A2 (pt) 2013-10-22
ZA200902822B (en) 2010-07-28
JO2653B1 (en) 2012-06-17
UA99109C2 (ru) 2012-07-25
SI2076494T1 (sl) 2010-11-30
NZ575615A (en) 2011-01-28
AU2007310925B2 (en) 2012-07-26
DE602007008124D1 (de) 2010-09-09
PT2076494E (pt) 2010-10-18
US20090325980A1 (en) 2009-12-31
IL198332A0 (en) 2010-02-17
DK2076494T3 (da) 2010-11-08
WO2008049806A1 (en) 2008-05-02
JP2010507615A (ja) 2010-03-11

Similar Documents

Publication Publication Date Title
JO2653B1 (en) Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB
JO2537B1 (en) Aryl-pyridine or pyrezinate compounds replaced with heterogeneous pentagonal rings used as inhibitors of MTB proteins
MX2010002461A (es) (carboxilalquilenfenil)feniloxamidas, metodo para su produccion y uso de las mismas como medicamento.
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
HRP20050103A2 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
MX2011012122A (es) Derivados de tiofeno.
MX2011012017A (es) Nuevos derivados azaciclicos como inhibidores de lipasa sensible a las hormonas (hsl).
BRPI0613754B8 (pt) compostos, éster de um composto, composições farmacêuticas que compreendem o composto, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por análogos de hormônio de tireóide e utilização dos compostos
HK1100559A1 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
MX2010008051A (es) Nuevos derivados de fluoroglicosidos aromaticos, productos farmaceuticos que comprenden dichos compuestos y uso de los mismos.
IN2012DN02502A (ja)
HK1130053A1 (en) 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
EA200970170A1 (ru) Производные 4-триметиламмоний-3-аминобутирата и 4-триметилфосфоний-3-аминобутирата как ингибиторы срт
HK1137011A1 (en) Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
NZ589911A (en) Styrylbenzofuran derivatives as inhibitors for beta-amyloid fibril formation and preparation method thereof
EA201101175A1 (ru) Фармацевтические комбинации 5-фторурацила и производных 1,4-дигидропиридина и их применение для лечения рака
NO20064601L (no) Mtp-hemmende aryl-piperidiner eller -piperaziner substituert med 5-leddede heterocykler
HK1136288A1 (ja)

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181025